For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Real-time index price for PHLX Semiconductor Index (SOX), along with buy or sell indicators, analysis, charts, historical ...

Finally, the world’s most valuable Health Care sector company by market cap, Eli Lilly (LLY ... including any listed on Toronto Stock Exchange and/or TSX Venture Exchange.

Eli Lilly has made a foray into the radiopharmaceuticals ... and also operates an R&D unit in Toronto, Canada. Analysts have suggested that the market for radionuclide-based cancer therapeutics ...

making it one of the most extensive so far on a class of medicines that includes Novo Nordisk’s Wegovy and Eli Lilly & Co’s Zepbound. The study, published on Jan 20 in the journal Nature ...

and Eli Lilly (NYSE:LLY), respectively. However, the new study led by Ziyad Al-Aly, a physician-scientist at the Veterans Affairs St. Louis Health Care System in Missouri, points to previously ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...